ArticleKidney international2018
Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.
Article in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Beyond Genotype: Multidomain Biomarker-Integrated Risk Scores Reveal Prognostic phenotypes Among Individuals with High-RiskmedRxiv : the preprint server for health sciences · 2026Article
- Novel biomarkers for CKD risk stratification: a literature review.Jornal brasileiro de nefrologia · 2026Review
- APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2025Article
- Interaction BetweenKidney international reports · 2025Article
- Article
- Article
- Renal Papillary Necrosis (RPN) in an African Population: Disease Patterns, Relevant Pathways, and Management.Biomedicines · 2022Review
- APOL1 Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study.American journal of nephrology · 2022Article
- Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.Diabetologia · 2021Observational
- Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Article
- APOL1 at 10 years: progress and next steps.Kidney international · 2021Article
- Observational
- Primary care referrals to nephrology in patients with advanced kidney disease.The American journal of managed care · 2020Article
- Article
- Apolipoprotein L1 Gene Testing Comes of Age.Kidney360 · 2020Article
- BioPETsurv: Methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials.PloS one · 2020Article
- Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Article
- JC Viruria Is Associated With Reduced Risk of Diabetic Kidney Disease.The Journal of clinical endocrinology and metabolism · 2019Article
- Mechanisms of Injury in APOL1-associated Kidney Disease.Transplantation · 2019Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
G1/G2 variants in the Apolipoprotein L1 (APOL1) gene are associated with end-stage renal disease (ESRD) in people with African ancestry. Plasma biomarkers may have utility for risk stratification in APOL1 high-risk individuals of African ancestry. To evaluate this, we measured tumor necrosis factor receptor 1/2 (TNFR1/2) and kidney injury molecule-1 (KIM1) in baseline plasma specimens from individuals of African ancestry with high-risk APOL1 genotype. Biomarker association with a composite renal outcome of ESRD or 40% sustained decline in estimated glomerular filtration rate (eGFR) was then determined and then assessed as improvement in area under curve. Among the 498 participants, the median age was 56 years, 67.7% were female, and the baseline eGFR was 83.3 ml/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.